These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33526787)

  • 1. Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer.
    McGuire JJ; Frieling JS; Lo CH; Li T; Muhammad A; Lawrence HR; Lawrence NJ; Cook LM; Lynch CC
    Nat Commun; 2021 Feb; 12(1):723. PubMed ID: 33526787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6: a bone marrow stromal cell paracrine signal that induces neuroendocrine differentiation and modulates autophagy in bone metastatic PCa cells.
    Delk NA; Farach-Carson MC
    Autophagy; 2012 Apr; 8(4):650-63. PubMed ID: 22441019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
    Thulin MH; Määttä J; Linder A; Sterbova S; Ohlsson C; Damber JE; Widmark A; Persson E
    Prostate; 2021 Jun; 81(8):452-462. PubMed ID: 33822400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mouse bone marrow-derived mesenchymal stem cells induce macrophage M2 polarization through the nuclear factor-κB and signal transducer and activator of transcription 3 pathways.
    Gao S; Mao F; Zhang B; Zhang L; Zhang X; Wang M; Yan Y; Yang T; Zhang J; Zhu W; Qian H; Xu W
    Exp Biol Med (Maywood); 2014 Mar; 239(3):366-75. PubMed ID: 24500984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells.
    Brizuela L; Martin C; Jeannot P; Ader I; Gstalder C; Andrieu G; Bocquet M; Laffosse JM; Gomez-Brouchet A; Malavaud B; Sabbadini RA; Cuvillier O
    Mol Oncol; 2014 Oct; 8(7):1181-95. PubMed ID: 24768038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer.
    Sung SY; Liao CH; Wu HP; Hsiao WC; Wu IH; Jinpu ; Yu ; Lin SH; Hsieh CL
    PLoS One; 2013; 8(8):e71637. PubMed ID: 23977098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity.
    Borghese C; Cattaruzza L; Pivetta E; Normanno N; De Luca A; Mazzucato M; Celegato M; Colombatti A; Aldinucci D
    J Cell Biochem; 2013 May; 114(5):1135-44. PubMed ID: 23192362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties.
    Liu YQ; Wang SK; Xu QQ; Yuan HQ; Guo YX; Wang Q; Kong F; Lin ZM; Sun DQ; Wang RM; Lou HX
    Acta Pharmacol Sin; 2019 May; 40(5):689-698. PubMed ID: 30171201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-bone microenvironmental interactions promotes STAT3 signaling.
    Henderson VM; Hawsawi O; Burton LJ; Campbell T; Trice K; Dougan J; Howard SM; Odero-Marah VA
    Mol Carcinog; 2019 Aug; 58(8):1349-1361. PubMed ID: 31045290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.
    Zhang S; Gera L; Mamouni K; Li X; Chen Z; Kucuk O; Wu D
    Oncotarget; 2016 May; 7(19):27489-98. PubMed ID: 27050371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6/interleukin-6 receptor complex promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells.
    Xie Z; Tang S; Ye G; Wang P; Li J; Liu W; Li M; Wang S; Wu X; Cen S; Zheng G; Ma M; Wu Y; Shen H
    Stem Cell Res Ther; 2018 Jan; 9(1):13. PubMed ID: 29357923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone-metastatic prostate carcinoma favors mesenchymal stem cell differentiation toward osteoblasts and reduces their osteoclastogenic potential.
    Fritz V; Brondello JM; Gordeladze JO; Reseland JE; Bony C; Yssel H; Noël D; Jorgensen C
    J Cell Biochem; 2011 Nov; 112(11):3234-45. PubMed ID: 22009438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis.
    Cook LM; Frieling JS; Nerlakanti N; McGuire JJ; Stewart PA; Burger KL; Cleveland JL; Lynch CC
    Oncogene; 2019 Oct; 38(44):6959-6969. PubMed ID: 31409900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p62/SQSTM1 is required for cell survival of apoptosis-resistant bone metastatic prostate cancer cell lines.
    Chang MA; Morgado M; Warren CR; Hinton CV; Farach-Carson MC; Delk NA
    Prostate; 2014 Feb; 74(2):149-63. PubMed ID: 24122957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 maintains bone marrow-derived mesenchymal stem cell stemness by an ERK1/2-dependent mechanism.
    Pricola KL; Kuhn NZ; Haleem-Smith H; Song Y; Tuan RS
    J Cell Biochem; 2009 Oct; 108(3):577-88. PubMed ID: 19650110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma.
    Tu B; Du L; Fan QM; Tang Z; Tang TT
    Cancer Lett; 2012 Dec; 325(1):80-8. PubMed ID: 22743617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer.
    Han Z; Wang X; Ma L; Chen L; Xiao M; Huang L; Cao Y; Bai J; Ma D; Zhou J; Hong Z
    Oncotarget; 2014 Sep; 5(18):8416-28. PubMed ID: 25261365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchymal stem cells recruited by castration-induced inflammation activation accelerate prostate cancer hormone resistance via chemokine ligand 5 secretion.
    Yu Y; Zhang Q; Ma C; Yang X; Lin R; Zhang H; Liu Y; Han Z; Cheng J
    Stem Cell Res Ther; 2018 Sep; 9(1):242. PubMed ID: 30257726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells.
    Liu C; Zhu Y; Lou W; Cui Y; Evans CP; Gao AC
    Prostate; 2014 Feb; 74(2):201-9. PubMed ID: 24307657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
    Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.